<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Acad Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">J Am Acad Dermatol</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of the American Academy of Dermatology</journal-title></journal-title-group><issn pub-type="ppub">0190-9622</issn><issn pub-type="epub">1097-6787</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10922724</article-id><article-id pub-id-type="pmcid-ver">PMC10922724.319</article-id><article-id pub-id-type="pmcaid">10922724</article-id><article-id pub-id-type="pmcaiid">10922724</article-id><article-id pub-id-type="manuscript-id">NIHMS1952998</article-id><article-id pub-id-type="pmid">37984720</article-id><article-id pub-id-type="doi">10.1016/j.jaad.2023.11.020</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1952998</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1952998</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Merkel cell carcinoma recurrence risk estimation is improved by integrating factors beyond cancer stage: a multivariable model and web-based calculator</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>McEvoy</surname><given-names initials="AM">Aubriana M.</given-names></name><degrees>MD, MS</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hippe</surname><given-names initials="DS">Daniel S.</given-names></name><degrees>MS</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lachance</surname><given-names initials="K">Kristina</given-names></name><degrees>MS</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Park</surname><given-names initials="S">Song</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cahill</surname><given-names initials="K">Kelsey</given-names></name><degrees>BS</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Redman</surname><given-names initials="M">Mary</given-names></name><degrees>PhD</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gooley</surname><given-names initials="T">Ted</given-names></name><degrees>PhD</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kattan</surname><given-names initials="MW">Michael W.</given-names></name><degrees>MBA, PhD</degrees><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nghiem</surname><given-names initials="P">Paul</given-names></name><degrees>MD, PhD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A4" ref-type="aff">4</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A1"><label>[1]</label>University of Washington, Department of Medicine, Division of Dermatology, Seattle, WA</aff><aff id="A2"><label>[2]</label>Washington University in St. Louis, Department of Medicine, Division of Dermatology, St. Louis, MO</aff><aff id="A3"><label>[3]</label>Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA</aff><aff id="A4"><label>[4]</label>Seattle Cancer Care Alliance, Seattle, WA</aff><aff id="A5"><label>[5]</label>Cleveland Clinic, Department of Quantitative Health Sciences, Cleveland, OH</aff><author-notes><corresp id="CR1"><label>*</label>Correspondent for JAAD communications: UW Medicine at South Lake Union Biotech &amp; Medical Research Hub, 850 Republican St, Box 358050, Seattle, WA 98109. Lab Phone: 206-221-4594. Lab Fax: 206-221-4364</corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>19</day><month>11</month><year>2023</year></pub-date><volume>90</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">457420</issue-id><fpage>569</fpage><lpage>576</lpage><pub-history><event event-type="nihms-submitted"><date><day>31</day><month>12</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-01 00:25:24.073"><day>01</day><month>03</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1952998.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background</title><p id="P1">Merkel cell carcinoma (MCC) recurs in 40% of patients. In addition to stage, factors known to affect recurrence risk include: sex, immunosuppression, unknown primary status, age, site of primary tumor, and time since diagnosis.</p></sec><sec id="S2"><title>Purpose</title><p id="P2">Create a multivariable model and web-based calculator to predict MCC recurrence risk more accurately than stage alone.</p></sec><sec id="S3"><title>Methods</title><p id="P3">Data from 618 patients in a prospective cohort were used in a competing risk regression model to estimate recurrence risk using stage and other factors.</p></sec><sec id="S4"><title>Results</title><p id="P4">In this multivariable model, the most impactful recurrence risk factors were: AJCC stage (p&lt;0.001), immunosuppression (hazard ratio 2.05; p&lt;0.001), male sex (1.59; p=0.003) and unknown primary (0.65; p=0.064). Compared to stage alone, the model improved prognostic accuracy (concordance index for two-year risk, 0.66 vs. 0.70; p&lt;0.001), and modified estimated recurrence risk by up to 4-fold (18% for low-risk stage IIIA vs. 78% for high-risk IIIA over five years).</p></sec><sec id="S5"><title>Limitations</title><p id="P5">Lack of an external data set for model validation.</p></sec><sec id="S6"><title>Conclusion / Relevance</title><p id="P6">As demonstrated by this multivariable model, accurate recurrence risk prediction requires integration of factors beyond stage. An online calculator based on this model (at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://merkelcell.org/recur" ext-link-type="uri">merkelcell.org/recur</ext-link>) integrates time since diagnosis and provides new data for optimizing surveillance for MCC patients.</p></sec></abstract><abstract id="ABS2" abstract-type="summary"><title>Capsule Summary</title><p id="P7">
<list list-type="bullet" id="L1"><list-item><p id="P8">We describe a personalized recurrence risk calculator for Merkel cell carcinoma that integrates stage, sex, age, primary tumor site, immunosuppression, and unknown primary status to improve prognostic accuracy.</p></list-item><list-item><p id="P9">A web-based tool also integrates time since initial treatment, providing new guidance for optimized surveillance of Merkel cell carcinoma.</p></list-item></list>
</p></abstract><kwd-group><kwd>Merkel cell carcinoma</kwd><kwd>prognosis</kwd><kwd>recurrence</kwd><kwd>risk calculator</kwd><kwd>nomogram</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>